COVID-19 vaccine response drops significantly after 6 months in patients with IMIDs – Healio

Add topic to email alerts

Receive an email when new articles are posted on

Back to Healio

COVID-19 antibodies are significantly reduced by 6 months post-vaccination among patients with immune-mediated inflammatory diseases, according to data published in The Journal of Rheumatology.

However, individuals with diseases such as rheumatoid arthritis and systemic lupus erythematosus continued to see positive impacts to immunogenicity with fourth and fifth doses of COVID-19 vaccines, the researchers wrote.

Currently, individuals with immune-mediated inflammatory diseases (IMIDs) may be unsure about the value of COVID vaccination beyond the primary series, study author Sasha Bernatsky, MD, PhD, of McGill University, in Montreal, told Healio. This is particularly concerning since immunosuppressant therapy may put individuals at higher risk for SARS-CoV-2 transmission.

On the other hand, social vaccine fatigue has caused many individuals to decline additional COVID boosters after the primary series, she added. Since COVID-19 infection is a potentially fatal and vaccine-preventable co-morbidity, it is vital that individuals with IMIDs have access to relevant information that will help them decide when to get their next COVID vaccination.

To examine how time since last vaccination impacts serologic responses to COVID-19 vaccination and infection in patients with IMIDs, Bernatsky and colleagues conducted a study of 1,823 adults (mean age, 53.2 years) with various relevant conditions. The cohort was recruited from eight cities across Canada beginning in early 2021. Dried blood spots or sera, as well as self-reported data, were collected at enrollment, then 2 to 4 weeks, and subsequently 3, 6 and 12 months, post-vaccination. Participants either collected dried blood spots at home and mailed them for analysis, or had sera analyzed at local centers, depending on their location.

Sasha Bernatsky

Samples underwent automated enzyme-linked immunosorbent assays to measure log-transformed anti-receptor-binding-domain (RBD) titers and anti-nucleocapsid IgG. The effects of each covariate on anti-RBD titers were expressed as exponentiated beta coefficients.

According to the researchers, log-transformed anti-RBD titers were positively associated with female sex, number of vaccine doses, self-reported COVID-19 infections between 2021 and 2023, and negatively associated with use of prednisone, anti-TNF agents and rituximab (Rituxan, Genentech) either the originator or biosimilars. Titers were also negatively associated with time since last vaccination, especially beyond 210 days (exponentiated coefficient = 0.88; 95% CI, 0.8-0.95).

Vaccine doses four and five were associated with positive effects on anti-RBD serology, the researchers wrote.

Our data suggest that these individuals should continue to consider additional doses when more than 6 months has elapsed since last vaccination or infection, Bernatsky and colleagues wrote.

Bernatsky said she was a bit surprised that rituximab demonstrated such strong effects (adjusted exponentiated coefficient = 0.23; 95% CI, 0.1-0.53) on lowering post-vaccination immune response, despite the cohort containing only 44 patients on rituximab.

However, this is a fairly robust finding across studies, so it is something we need to pay attention to, she told Healio.

These findings may help individuals personalize vaccination decisions, including consideration of additional vaccination when more than 6 months have elapsed since last COVID vaccination/infection, she added.

Bernatsky highlighted further research to be done in this area.

The intricate relationships between all these variables age, sex, race/ethnicity, number and timing of vaccination, type of vaccinations, past medical history and the details of medications received need to be carefully modelled for us to truly understand if we can personalize vaccine decisions, she said. That is, can we offer strategies tailored to each patients needs?

According to Bernatsky, the current analyses considered medication exposures only at the time the subject enrolled in our study.

We would like to undertake more detailed analyses of past medications and doses in order to identify those with higher or lower immune system responses to vaccination, she said. The ultimate goal is to prevent COVID-related infections, hospitalizations and deaths.

Collapse

Disclosures: This study was supported by funding from the Vaccine Surveillance Reference Group and COVID-19 Immunity Task Force of the Public Health Agency of Canada. The views expressed here do not necessarily represent the views of the Public Health Agency of Canada.

Add topic to email alerts

Receive an email when new articles are posted on

Back to Healio

See the article here:

COVID-19 vaccine response drops significantly after 6 months in patients with IMIDs - Healio